Latest / Two PhDs on a Pod / Gut Health PRO
Transcript
- Dr. Guru Banavar: It started. Hey Momo. Hey Guru. All right. I have a question for you. If you took your car to a mechanic because you feel that your engine is sputtering, and then he kind of looks around outside and checks some things and then says, ⁓ you know what? There are no dents on this car. You don't need anything, and gives you back your keys and says, Hey, you don't have a problem. What would you do? Well, first of all I would find a new mechanic and then I would probably tell him to check himself because something's something's not right with his ⁓ expertise. Exactly. I mean Yeah. I mean that's what's going on with a lot of doctors, especially when you look at gastroenterologists, right, who are essentially intended to look across all types of Maladies of the gut, they look the traditional gastroenterology will look for structural issues, right? They look for a polyp or a blockage or something like that. Yep. But they don't focus on any functional issues like IBS, like bloating, right? These are 60% or more of the issues that GI doctors face. So when they're faced with a with a functional issue, they end up just doing trial and error. They don't have a prescribed way of going about. Well, that's because they lack molecular tests to actually figure out what the molecular features or what what molecular processes are causing those ⁓ those symptoms. Yeah. Lack of tools. Yeah, yeah. They they you know, they're flying blind. We need to help them out. So our ⁓ gut health protest can make a huge difference. And that's what we're gonna talk about today with our special guest, Dr. Michael Bass, a gastroenterologist, and hopefully. Everyone will stay around and listen to all the great points about how to improve your gut health. And if you're a doctor, how to improve the gut health of all of your patients. Yeah, this is a great analogy, Guru, that yeah, a mechanic without the tools to actually open up the engine and to actually examine all the parts and understand why the engine is broken, just being able to look around the car and and take basically pictures of the car and say, Hey, the car looks good. That is not very helpful for a lot of people. Of course, if you were in a car wreck and you dented the outside, then yeah, that's helpful, but that's ⁓ that's not all of the cases. ⁓ and ⁓ I laughed when you said an engine because ⁓ I've not had a car with an engine in five and a half years. So speak speaking of electric motors are the new thing. I know. And and and in my case, I have not had a car for about ten years now. So I'm not a car guy. And and maybe we'll talk about that some other day, okay? Just because I decided that public transportation and you know, just using Uber and other services are much more efficient for my life compared to owning a car and living with the overhead of that in New York City is just not worth it for me. Of course. Absolutely. So very smart. Very smart. So yeah, in summary here, what we're gonna talk about today is All of the molecular data, what Guru calls molecular software, ⁓ that now empowers physicians, gastroenterologists, to actually look under the hood, so to speak, and see all of the molecular details of what's going on in the intestine that are responsible for more than sixty percent of gastrointestinal symptoms. That's amazing. We're entering a whole new world today. So welcome to the episode. I am Momo, a biochemist. And I'm Guru, an AI expert. We're two PhDs on a pod. All right. ⁓ who's gonna go first? Well, ⁓ why don't you go first? What's on your radar? All right, I'll tell you what I'm excited about. I'm always excited about more things than we have time to share, but let's go about this one. So if you don't mind sharing the slides, I put together four photographs of the Pacific Northwest. So I've lived in Seattle now for six years. Look at that. Let me let me tell you. It is really difficult to plan any trips to go outside of the Pacific Northwest. You know, I used to be excited about so many places in the world, but wow, this is like a world class ⁓ area for so many different ⁓ things except tropical beaches. We don't have those, but we have a whole bunch of other things here. So yeah, I mean the summer here is crazy because our sun rises sometime around five o'clock in the morning and sets after nine PM. So we have these absolutely beautiful, gorgeous, sunny skies all day long for months. It's it's insane. So we take advantage of it and we go out and explore. And so here's Mount Rainier. This is one of the most famous parks in in the Pacific Northwest, Mount Rainier National Park. ⁓ let's go to the next one picture, man. Amazing. Yeah, this is my son and I woke up at four in the morning and hiked up and ⁓ man, it's amazing. ⁓ let's go to the next one. ⁓ This is actually crazy because this is literally like a forty-five minute drive from Seattle. And then it's a bit of a hike. It's three thousand vertical feet. So it's a it's a bit of a huffer and buffer. But look at this. This is crazy that you get to see this. And what's the name of this, ⁓ what's the name of this mountain range? Well, so this is the Cascades or North Cascades. ⁓ this is particularly this lake is called Lake Serene, and it's literally the very first ⁓ So right there on the edge of the city. ⁓ pretty amazing. So ⁓ next slide, please. And then yeah, in the in the Puget Sound, you can go sailing, you can go boating, you can go kayaking, all kinds of things. ⁓ just recently we went ⁓ whale watching, and yeah, we have ⁓ local resident pods of Orca whales, and they're here year round. And ⁓ the local tour operators can take you to view them and and watch their behavior and ⁓ It's pretty cool because you can get fairly close to them, you know, within nice distance. Next slide. And then yeah, this is another crazy thing. So this is literally like the the closest part of the Cascades to Seattle. This is ⁓ on Snoqualmy Pass. So Snoqualmy Pass is the major pass east of Seattle on I-90. And you just park on the pass, you know, by the road. And then this is called Snow Lake. It's ⁓ it's about an hour and a half hike. And yeah, it it's crazy that we have this. ⁓ I mean, this is just a few of hundreds of places that are super, super beautiful around here. So I'm excited about this. Yeah. Yeah. I wanna I wanna visit a few of these places next time I'm up there. I'm gonna go let's go. Because I told you, you know, because of Wyom on the one hand and also now my brother's gonna be there on the other hand. So And now some nature as well. Yeah. So I'll take you to all these cool places. And then I promised ⁓ in the last ⁓ episode I talked about mole and I promised that I would show pictures. And so this is this is the recipe from about fifteen fifties based on ⁓ historical records, and it's basically a combination of the new world foods and old world foods. So it's it's a it's a modified version of mole as it was developed in pre Columbian era, ⁓ but it's still delicious. This one is the one made with cocoa, the black mole. And ⁓ I'm just showing here the ingredients and sort of some some steps in cooking. You know, you gotta roast your vegetables to extract the most flavor from them and and roast the nuts with the spices and s and so on and soak the chile. ⁓ we are gonna actually post a recipe for this in just sho in the show notes so that others can reproduce this because black mole has a very unique flavor, like no matter How many different cuisines and meals you've tried. You have never tried black mole unless you tried it exactly. Like it's a very unique ⁓ flavor. Very cool. Very cool. I'm gonna try. All right, Guru. Go ahead, sorry. No, no, I'm gonna try this. I'm definitely gonna try this. Amazing. Amazing. Yeah. All right, Guru. Now what's on your radar? Okay. So look, you ⁓ showed a lot of things from nature. I'm gonna I'm gonna do the kind of the contrast to that, which is city life. City like the big city. Big Apple, right? In the in the Big Apple, right? And I I love the city, the city energy, the ⁓ kinds of ⁓ activities that you can do. A couple of things that happened in the recent past, I just wanna I just wanna show you one, which was a tall ship's parade that happened in the New York Harbor when the two hundred and fiftieth year, July fourth Independence Day celebrations. I love that. I love that. There were, I think, like fifty different ships from different countries that showed up. And all of them were like, you know, very fancy tall ships, all sail chips, by the way. Right. And ⁓ I was just mesmerized by them. And there were planes going around, you know, from different countries, from their military and everything, but there were also these tall ships. And I I took a couple, just I'm gonna show just a couple of pictures. One from India, which I noted. It's this is the INS. Sudar Shini, which is a 177-foot boat and it's 113 feet tall. And these guys have sailed for approximately 15,000 miles from all the way from Kochi, India, which is the hometown of this boat. They've sailed all the way to New York Harbor just by using wind energy. I mean, whenever I think about that, it's always fascinating to me how that how that it took them like a couple of months to get here. Right. You you see all the people on the on the masts, you see the people standing up, right? Those that's the crew. And they have been on this ship for that long and they got here. It was just amazing to see them. You know, we all not just waved, but we kind of sang and shouted and all of that good stuff. And the other ship I want to show you, right next to the the the Statue of Liberty was a ship from the US. This is the eighteen seventy seven tall ship called Elissa. And it's a historic ship which was built at the Galveston Historic Seaport in in Texas, apparently. And it's 152 feet long, 100 feet high, very, very beautiful ships. I mean, you just see these things. They're beauties, right? It's man made, but ⁓ some of the most exquisite man made objects, in my opinion. Yeah. No, absolutely. Love the sail layout. Yeah, yeah. And ⁓ it's amazing to me that ⁓ you know, the technology and the engineering. allows you to harvest essentially the wind energy and kind of navigate this wherever you want to go in you know in in in the right way with the speed and the direction and even with storms and and and big ⁓ waves and everything else. You know, they manage the whole thing. It's it was it was ⁓ an amazing thing for me. So that was one thing. The other thing I want to show you guys is, you know, I am always fascinated with the street musicians of New York. Okay. ⁓ I'm a musician myself. And I love to hear people who spontaneously create music. And the street musicians of New York are some of the best. And I keep ⁓ teasing people in other cities that our street musicians are better than their concert musicians. You know, and I've I'm actually I actually believe that. You know, I go to other cities and I go to these massive high paid ticket concerts. And and then I say, you know, the street musicians in New York are are way better than this stuff. So I want to show you an example of a street musician that I fell in love with in New York City. Somebody made a great short video of that. So I'm just gonna play that. Let's enjoy it for a minute and a half. For those for those who don't know Guru, how do you find these street musicians? Are they always at the same place or is it random? It's totally random. So so ⁓ actually it's b it's both, okay, to be honest. When when I get out of Grand Central Terminal every day when I go to the office and I'm walking by, I do see some musicians in some standard places, but they're all different musicians. So It's random in the sense that you don't know what to expect for any given day. Got it. But many times you're just walking somewhere, literally on the street, next to a park, next to some kind of monument, next to something. And there's just in the street corner, there are a couple of street musicians who've who are doing something that blows your mind. You know, sometimes I just stop there and I I just forget about the rest of the world because it's so good. I'm gonna show you that. So for people who want to do experience this who are visiting New York City, are there any particular areas of the city they should go or any particular time of the week they should go or particular time of the year? It's all around the year. And it's it's you know, go if you're in if you're here in the summer and you want to experience this anywhere that tourists hang out. you will see street musicians. There's no question in my mind. So you really don't have to look for it. You just walk around and you'll see it. Yeah. You'll just you just walk around the city and you will see n next to monuments, next to historical places, next to parks, wherever you go to eat, to, to see, to hang out, you'll see these guys on the street. So I'll show you an example. This is like a super I would call it a sophisticated type of mu music that's created by just two random strangers. who came together on the street and just decided to create an and this guy, Ari at home that I'm gonna show you, does this all the time. He just walks around the street and creates music with random strangers he meets. And I'm so fascinated with that lifestyle for him. And he just creates videos and I'm gonna show you one of them. What's going on here? What is happening? I'm Andrew. Alright, nice to meet you, bro. What is this? It's basically a guitarist's pedal board. I just pull out the violin. You're not a violin. It's violin. Wait, this is gonna be fire. I've never heard like a violin through guitar pedals. Tell me what kind of vibe you're feeling. Classic like cash money era New Orleans. Whoa! But with like four chords like classical style over it. Like a 145 thing. Okay, I got you. With like piano or harp support. ⁓ What? Possible. Wow. What do you think of that? What a show. No fireworks like the big concerts, but super unique. I know, man. It's like I you know, I get mesmerized by these things. I just stop and I forget about the rest of the world and I just stay there. And then I, of course, like, you know, give them a nice tip and everything. And that's why I love New York City. That's amazing. Super unique. And the dancing dude, wow. What the heck? And that guy who was dancing, he came up. And he rapped on top of this music for a little bit, like for a few minutes, just made up lyrics and rapped on top of that. And then some woman came and sang on top. You know, the whole the whole thing went on for like a whole hour. It was ridiculous. It was that is super unique. Like you cannot possibly prepare for that or recreate that. It's just the one moment in time and you gotta be there. It's crazy. That's right. That's right. So unique. Super cool, Guru. Thanks for sharing that. You bet. So ⁓ For Mike Bass? We're ready for Dr. Bass. Dr. Bass. Okay, get into the different mindset now. Let's go. Hi, everybody. I'm so happy to welcome Dr. Michael Bass, MD, to our show today. ⁓ Mike is ⁓ a really good friend of ours. He has been ⁓ very active in the gastroenterology world for a number of years. He was actually the founding medical director of OSHI Health and he's had a private GI practice for 14 years. He's now a global medical director here at VIOM. And one more thing that's super interesting about Mike is that he is a top voice on LinkedIn. So you might actually see a whole bunch of things from him on LinkedIn about all the latest news and analysis of various things in the gastroenterology community. ⁓ on a regular basis. I actually follow him and ⁓ learn a lot from ⁓ from everything he says. So so Mike, ⁓ welcome again. And ⁓ I would love to kind of start with a perspective from you about a modern gastroenterologist ⁓ as we as we know it. ⁓ you know there's there's so many good things about gastroenterology but there's also so many limitations. Right. People s are still practicing what they'd they'd been taught from ⁓ maybe decades ago. And there's a lot of functional aspects of gastroenter you know, GI conditions that ⁓ are pretty difficult to diagnose and pretty difficult to treat. So give us a little introduction to how you see the world of gastroenterology today, please. Of course. First of all, Guru Momo, thank you, thank you for for having me on. I'm a huge, huge fan of fan of this fan of this podcast. It's it's it's the best best healthcare healthcare podcasts out there. And and you know, I I might be slightly biased, but ⁓ it definitely it definitely is the case. So ⁓ yeah, so you know I've so I've been a a ⁓ private practice GI doctor for the last fourteen years. And you know so what I've seen is that we are great at telling you if there's a structural problem. So you know if somebody has cancer. Or if somebody has a polyp, or if they have a blockage. We can do all types of tests and we can tell you about that. But what we're not great at is managing the every day to day issues that frankly most most people have that that that come into our office. And so these are classified as these functional gastroisses where, you know, we've done all the testing and we don't see an actual structural problem. ⁓ you know, but there's some issue in how the bowel functions. And and you know, and this is irritable bowel syndrome, ⁓ you know, these are things like SIBO, even you know, visceral ⁓ abdominal wall pain. So, you know, the these these functional gastro issues are ⁓ make up close about fifty to sixty percent of all all outpatient GI visits. And, you know, frankly, we don't have tools, you know, adequate tools at least to manage these issues. ⁓ And then second is personalized personalized care. So diet is a big, big thing in GI. And so as of now, we have standard dietary protocols like this, like this low FODMAP diet. But what we know, and it this is something I've I've learned from from from a your podcast, not every food is is good for every person, right? So we need personalized dietary dietary recommendations. And in the world of GI right now, that's an area that's extremely lacking. Also, Mike, ⁓ I've heard that the low FODMAP diet is not really sustainable. What do you what do you have to say about that? That's a hundred percent correct. So you know, I I think the the standard practice is to basically print out print out a patient a, you know, four or four or five page handout giving them a list of all these foods that are that are that that are low in in in FODMAP and then you know having them have them try to try try to follow it them themselves. But that diet is so exclusionary. So nobody can follow it. ⁓ you know, and it's just there's there's kind of a in general there's a lot of mis mis misconceptions in like how to utilize that low FODMAP diet. Some some people think that they have to stay on the low FODMAP diet for the rest of their life. And you know that's that's not really protocol. But i ⁓ to to answer your question, Momo, it's extremely difficult to to follow a low FODMAP diet. Yeah, and also Mike, ⁓ you've told us on various occasions that ⁓ the treatment protocols are quite ⁓ I would call it hit or miss, right? You you kind of take a guess as to what might be going on and you try a few protocols and then if it doesn't work, you switch and sometimes it may take multiple tries before you can you can get it right. So how did we you know how did we end up over there? Yeah, well so I mean that it it really kind of goes back to the fact that, you know, there there's no really ⁓ objective test as of now that tells us, I mean, e you know, so basically with these these functional gastro issues like IBS C IBSD. So as of now, there's no standard test that indicates whether you have IBS C IBSD. ⁓ so it's more of, you know, based on clinical symptoms history and then basic tests that rule out structural issues if it's indicated. But you know, even if we come to that conclusion that a patient truly does have a functional issue, you know, there's no test that actually breaks breaks it down and says, you know, what is the actual pathway? What's the issue, you know, with with with somebody who has IBSC. and so if we don't know what the actual pathway issue is, then you know, we can't there's not a lot of guidance just in terms of what medication do we start first. So often it is, you know, trial trial and error. So, you know, s for for a patient who has who has IBSC, we might start them on on on Lin Lin's S first line, but, you know, there's no guidance. I mean it it's it's just kind of rash you know, there's like no rationale to like why you would start somebody on on this medicine Lin Lin's essay versus versus versus am and TISA, it's it's all trial and error. And then so if we start somebody on Linsac and it doesn't work or they have they have side effect profiles, they follow up and they see us in in in three to six months and and they say that med's not working. So then we'll give them something else and and basically pray that that it works. But you know there's there's like no ⁓ objective data points right now in GI that kind of helps tailor personalized treatment. Yeah. Mike, you know speaking of ⁓ objective tests, ⁓ that's the whole Central point about this episode is that ⁓ we now actually do have an objective test in the market. And that's called the Viome Gut Health Pro. And ⁓ in one of the previous episodes, we had kind of just mentioned that it was launched just a few weeks ago. But I would like to dive into the details of this test and have you explain to us what this test can do for gastroenterologists and how it's useful, how it can be incorporated into standard clinical workflows, what the utility is at each step, are different kinds of scenarios and everything. So so we can actually make this test available to most patients out there through their doctors. So let me just share with you this picture that I'd previously shown. To our audience here about our gut health protests. So it's it's something that is considered today a very advanced gut health test. In fact, it is the most advanced gut health test that I know of because it has, first of all, it has the most advanced underlying molecular technology, which is RNA technology, which we'll talk about in just a minute. And it has a number of molecular AI. algorithms that is working for it. But even more importantly, I think this is looking at a very comprehensive view of your gut. It is looking across many different diseases. It's looking across many, many pathways. It's looking at multiple different activities of the gut microbiome. And it is surfacing only those that should give a lot of clues to a doctor and to the patient about what to do. So this test, which ⁓ which ⁓ we're gonna go into in in detail, is based on a technology that we've talked about quite a lot, Momo and I, which is metatranscriptomics. So Momo, do you wanna explain and refresh people on on what this is and then we'll get back to Mike. Yeah, let's refresh people on DNA versus RNA. So, yeah, the vast majority of tests out there are looking at DNA, some some analysis of DNA. And DNA, I want everyone to think about as what is your risk at birth for a disease? And so this person here, this is a Crohn's patient. It's their small intestine. And their risk at birth may have been high or low. It doesn't really matter. What is what is happening today can vary from month to month. And so on the left side, what we're showing is that. the the intestine, the small intestine of the per of the patient, ⁓ in their remission. So they're healthy and they have a normal life. They can do anything they want. They basically have no symptoms. But just a few weeks later, ⁓ they enter a flare and the result of that is that inflammation that you can see on the right on in the middle picture. ⁓ so now their life is turned upside down. They basically cannot do things that they want to do and they're in pain 24 hours a day and there really isn't a any ⁓ you know, there's a structural change here, but there really isn't any molecular change that anyone can observe with DNA, because if you analyze the DNA of this intestine one month apart, you're going to get the exact same sequence back. It's the DNA of the person that they were born with. But if you look at the RNA of that intestine a month apart, you can see a black and white difference, in this in this case, ⁓ blue and red difference that's shown on the right graph. So this is not something that we have discovered. This is known to the world. That the gene expression profile is the one that determines whether a tissue is going to be diseased or healthy. It's not really the DNA. DNA plays a very minor role. And so this is basically the explanation of why RNA analysis is so much more relevant to a disease state than DNA analysis. Yeah, and and you know, the other interesting and super important point here is that it can be modulated, right? It can be modulated through diet and lifestyle. So, you know, the gut microbiome, which is a big part of what happens in your overall health and disease state in your gut, is modifiable, right? You can you can actually improve the expression levels by feeding it the right stuff, or you can even populate it with more probiotics and other forms through food and everything, so that you can increase the the population of healthy commensal, useful bacteria. And you can You know, over time you can actually convert a potentially inflamed or or or not so healthy gut into a healthy gut if you have the right diet and lifestyle. Yeah. I mean, I really want to elaborate on that a little bit because people may not be familiar with how can you modulate the microbiome. The microbiome basically is alive because you feed it. It doesn't really survive on thin air or, you know, nitrogen from the atmosphere. It real literally feeds on the foods that you consume. And so depending on what you consume, you're going to feed certain members of the microbiome, and they're going to be producing certain chemicals or metabolites that are going to then affect our own tissues. And the example that I think everyone gets is when you're making beer, you're actually doing this. You're modulating the micro the microbiome. In this case, you have only one species. It's Saccharomyces cereviciae, the brewer's yeast, and you're supplying it with food, which is which is barley, malted barley. And it produces ethanol for you and some other flavors. The more barley you add, the more ethanol it will make. And so if you want to modulate how much ethanol your yeast makes, you modulate the amount of material you feed it. And that's exactly the principle of our approach, except that the complexity here is such that an average person will have about twelve hundred species of microbes, and each species has many, many metabolic p possibilities. And which ones are actually active and which ones are associated with the disease is what we're going to now discuss. Exactly. And and so this ⁓ DNA versus RNA difference, I think, is very, very critical in deciding why a test can be objective. So, and it's not just us saying it, it turns out that there was an international panel that got together and came up with a guidance statement. And when you look at All of the points they make in that guidance statement. This is, by the way, in the Landsat Gastroenterology and Hepatology, you'll see that all of those pa statements are prohibiting or discouraging the use of DNA-based tests like metagenomics tests. For microbiome analysis. For microbiome analysis, right? So when you say You know, somebody comes in and says, hey, you know, we use shotgun metagenomics, and you know, it sort of sounds fancy, but at the end of the day, it's doing DNA analysis of your microbiome, and that is only telling you what is the static content potentially of your of your microbiome, but it's not telling you what's actually going on in there. Whereas what we need to do is a functional assessment. And the functional assessment can only happen when you know what the current activity of your microbiome is. So One of the major points that this consortium made is that it should be a validated functional measurement in order to for it to be useful. And then it says over and over, like the statement 20 over here, it says function should be prioritized over just inference. You know, measurement of the function should be prioritized over the inference of function. It also says you need to have functional reference ranges. It need you need to have disease-specific evidence. And you to ha you need to have high quality and ⁓ reporting from your laboratory processes. And all of the statements and the criteria that they put forward in this particular consensus statement, I would say have has been met by VIOM. In fact, the VIOM test is the only one that meets all these criteria. There's no other commercially available test that meets all these criteria. Mike, do you ⁓ do you take this ⁓ this gastroenterology hepatology statement seriously and how you know widespread is this is this ⁓ in in the gastro community? You know, definitely. I mean I think probably just I mean just just to kind of s start it off, ⁓ you know, most GI doctors now ⁓ currently do not use stool microbiome testing because most of the prior tests are based on Medignomics, which tells you the the presence of of certain strains, but doesn't tell you actual function. And you know, and and I the you know big big point there is that, you know, different bacteria, they can have different function in different people. So there's not one universal and and guru tell me if I'm wrong, but there's not one universal bad gut bacteria. So that same bacteria in one person can be good. That bacteria in somebody else could be bad, right? So ⁓ and Mike The same bacterium and the same person with different micronutrients can turn from bad to good or good to bad. Right. Okay. So so it's it's it's about the in environment that that bacteria is in. It's not necessarily about exactly. I mean, going back to the example of yeast and ethanol, if we establish that there is just the right amount of ethanol to keep a person healthy, then you want to feed that yeast just the right amount of barley. Let's say enjoy food, right? If if that person if if you feed ⁓ too much barley to the yeast, it'll overproduce ethanol and now that's harmful. If you underfeed it, it'll produce too little and that's not healthy because it's needed. And that's how you modulate basically how what is the metabolic output of your microbiome using micronutrients. So that's basically the whole platform of biome is we can make most people's microbiome healthy by tuning their functions. Yeah, that and and I mean that that that makes that makes perfect sense to me because ⁓ you know, a lot of the standard tests that that have been used and and I'm not gonna name names, but ⁓ you know, basically we'll have we'll have patients come in with this with this laundry list of of of different bac bacteria that are that are fifteen, fifteen pages long. And honestly we don't know what to do, right? Because you know, there because you know, just just because something's positive, like that that doesn't there's no management change. So so it's not actionable. And so one of the reasons why why I love biomes tests is that, you know, it just doesn't give you this this laundry list of like different tax. It tells you, you know, this is the problem, you know, this is this is the function and this is what you do do do about that function. So I mean I I I think this tracks definitely with with what I'm seeing in practice. Guru, you have some slides on what ⁓ GH Pro yeah, there we go. So yeah. So you know That was actually a perfect segue into this slide. What what Mike said, I was just gonna make us a shift over to this next slide. So when you take the gut health protest, it assesses many areas of functional health and specifically seven areas that I've mentioned over here. ⁓ we could dive into the details of this, but each of these areas is clearly important to your health and potentially. To illness in your gut. Any given functional health area, like for example, I'm just going to pick one, gas production. It could have multiple pathways that impact gas production, right? You can have methane gas, you can have sulfide gas, you can have ammonia gas. We talked about this in an entire episode. If you've listened to one of our episodes earlier, we talked about What those pathways really mean. How does our lab process, which Momo explained in yet another episode, how does that process lead into the assessment of specific pathways? So if you're interested in exactly how we do that, please go back and look at our previous episode on the topic of gas production. But that set of pathways are then aggregated into a gas production functional health score that can then be used for assessment for you know what should we do, right? Is it is it nutritional interventions? Is it ⁓ potentially pharmacological intervention in some cases, right? And it could be some lifestyle changes, it could be various sets of things that that we can we can recommend. ⁓ I want to pick Besides gas production, I also want to pick gut lining health as another super important thing, as we've talked about in some episodes. You have a a barrier between your gut, which is ⁓ an anaerobic environment, and ⁓ your blood. And so you don't want any kinds of molecules going back and forth between those two those two environments. And if something like that happens, like for example, if TMA, which is a trimethylamine. ⁓ molecule moves from your gut to the blood, that's not good because it's, you know, it can get converted into TMAO and that can lead to atherosclerosis. And ⁓ the other way around is also true. If things come from the blood into the gut, that can lead to oxidative stress because as I said before, the gut is an anaerobic environment. You don't want oxygen coming into the into the gut either, right? So you want to first assess gut health gut lining health and then decide whether there are ways in which you can you can actually control that. It turns out there are many ways of handling that, both through nutrition, through supplements and so forth. So each one of these areas can give us insights into how to manage it. And I'm I want to go to the next slide where we have a little more information. Actually I'm gonna I'm gonna go to this slide first. Hey Guru, I want to say something here. So I think that I think that many gastroenterologists have maybe heard from their colleagues saying, ⁓ they're talking about leaky gut, this sort of mythical phenomenon that doesn't exist, right? That used to be the case ten years ago. Now there are absolutely premier scientific publications showing not only that leaky gut is a real thing, but it's actually involved in many, many different pathologies and many different diseases. So if don't don't just dismiss gut lining health as, ⁓ that's leaky gut. There's now very solid publication literature list on that. So please take it seriously because it is very important for your patients. Yeah. And also, Momo, ⁓ at the you know, along the same lines, there are ⁓ quite a few good studies now that are showing the impact of food and supplements on leaky gut as well. So we you know we can start we can start to look at what kinds of interventions are possible and you know how to use that in in in in daily life. Right. So The the the point I want to make was these pathways that we're talking about all are associated with various disease states. We've talked about IBS constipation and IBS diarrhea. Those are disease states, and there are specific pathways for gas production, for example, methane. ⁓ we know that methane contributes to IBS constipation. Gut lining health, there are Pathways underneath gut lining health for inflammatory pathways for mucin degradation, so forth. Those kinds of pathways are associated with ⁓ non-alcoholic fatty liver disease, ⁓ type 2 diabetes, multiple such diseases, right? So turns out that this gut health protest focuses on six diseases and gives you a specific disease risk score for these common. GI related diseases. IBS constipation, IBS diarrhea, inflammatory bowel disease, which we showed a picture of earlier, non-alcoholic fatty liver disease, type 2 diabetes, and depression. So, Mike, I wanna I wanna go back to you and first ask you. Is this set of diseases what you would consider to be common GI related diseases and and what what you would normally look for in your patients and and how you how you want to go ahead and treat those? Definitely, yeah. I mean so so these six, the reason why we chose these six is because they reflect several do domains that frequently overlap in in in clinical practice. So, you know, I how how I sort of view it as there there's there's basically five five different areas. So one is functional and and motility issues, two is inflammatory processes, three is the gut liver by by allergy, four is metabolic health, and five is that gut brain access. So all six of these fall fall in with the within those those those five broader subtypes. And so you know it it's it's common patterns that that we see in in clinical practice and all of them are are linked. Yeah. And so in this ⁓ in this picture, what you see is a clinician report on the right hand side, which says that this particular patient has a high risk for IBS type C, that's constipation, and fatty liver disease. And there is a an expanded view of IBS type C where it says you can see that this risk is six point ⁓ four. That's on a scale of zero to ten, anything that is more than five. Is flagged as a high risk. And that is the essentially the cumulative odds for a person to have that disease, IBS type C, given that the pathways associated with that disease are not in an optimal state relative to a to us relative to our reference population. Can I put that in the perspective ⁓ of, for example, Alzheimer's? People say if you're Homozygous, so you carry two genes for ApoE4, you have the highest risk of Alzheimer's. That's about an eight-fold higher chance of Alzheimer's. And here we have a range of five to ten. So that's a ballpark, very high risk, right? Yep. Exactly. We did we actually published the data behind all this risk assessment and showed exactly how the the arts ratios are calculated and how it is ⁓ ⁓ aggregated ⁓ for a given disease. And ⁓ we did that analysis in an independent validation cohort of more than fifteen thousand people. So this is a very large cohort and we validated this data in this very large cohort. So this is not just from a small study or from a sort of a low powered study. This is a really large population compared to a reference population of more than twenty thousand people. So ⁓ it should definitely be taken very seriously. ⁓ so Mike, I would ask you how would you look at the ⁓ the pathways, the clinical notes next to it, and the nutritional recommendations that come right next to that? Yeah, so so for IBSC, I d this is a common, common patient that that we see in in practice. So, you know, basically the patient's gonna have difficulty going to the bathroom, bloating, abdominal pain. And so and they've had all of the standard tests, standard workup that rule out, you know, structural problems like cancer. ⁓ so now we have this this patient that's that's labeled as as IBSC based on based on clinical history and and and other tests that have that have ruled out other structural processes. So what do you do with that with that IBS C patient? So if we don't have this this info, you know, it really is a trial and error process. Maybe we Tell them to increase fiber, tell them to increase fluids, maybe st start them on some on some stimulant laxatives. But without this detailed pathway info, we don't know if if if any of that's gonna actually work. So, you know, ⁓ what what what this test and and just looking at at this pathway breakdown now, so at so as you see on the very bottom, that methane gas pathway is is off. So what that what that tells me. So there's there's either either two things. So one, there's some issue with gut transit. So if stool sits in inside the colon for an extended period of time, all the bacteria inside the stool in inside the colon act upon that stool and increase the amount of of methane gas. Or you can have by itself a overgrowth of just metho ⁓ methogenic bac bacteria. So it's kind of like the, you know, chicken or or or or egg problem. But you know, ba based on this pathway, I would focus on the methane aspect of it. So I would I would want to, you know, work on on transit, either starting him on medications that that that actually help transit, like Miralax, Lin, Lin, Lin Zas, AMA, AMATISA, and then use those use those dietary recommendations there to formulate a more tailored and tailored dietary approach. So in in your standard patient who who who has constipation, you might tell them to increase the amount of fiber. The problem with this case is that, you know, if you increase the amount of fiber, then you get might actually make it worse because fiber creates more methane. And so many patients when we when we tell them, you know, just just in in in increase the amount of of of fiber, they they actually get worse. ⁓ but you know, we don't we don't really know that that mechanism wise. So, you know, s a a a breakdown like but like this, I would see that that methane pathway was was was off. I would not tell them to have more more fiber. I would follow the follow those dietary recommendations and and I would start them on a medication that helped the gut move. Exactly. Exactly. So, you know, what is interesting to me over here is that ⁓ you know, somebody might think that ⁓ IBS constipation is ⁓ is like one monolithic thing, but it's actually potentially multiple pathways that could be wrong with it, right? So it's like the same symptom, constipation, you might end up having multiple potential root causes. Right? It could be the methane that you were talking about, Mike. Or it could be sulfide production, we go in the wrong direction, could be bile acid, secondary bile acids, it could be short-chain fatty acid, it could be serotonin, it could be any one of these pathways. And depending on which pathways are not going in the right direction for a given individual, we can take the right actions as Mike was describing. Right? Have we talked about pathways yet? Have we defined those? Well, we had a whole episode on pathways, but ⁓ we should probably take take a moment to to reintroduce those. So Momo, go ahead. ⁓ well, ⁓ I mean the example I gave earlier with brewer's yeast making y ethanol from ⁓ malted barley, that's basically a pathway. What it is is a series of biochemical reactions that converts a micronutrients from our food into a chemical or metabolite that may have a physiological function in humans, such as lipopolysaccharide, TMA that you mentioned earlier, butyrate, ⁓ hundreds of these compounds. So that's basically a pathway. Exactly. Exactly. And and you see over here in this particular picture, we are showing these five specific pathways that are associated with constipation. And any one or more of those pathways can be out of balance. And that may be the reason why you have constipation. And When you know which of these pathways are not doing well, you can focus your intervention and your treatment plan to those pathways specifically. Right? And and to make things more complicated, even within each one of those pathways, the intervention in different people will be different. ⁓ boy. Okay. Yeah. Yeah. Yeah. So that's basically it the level of data and the level of complexity of this biology cannot be just you know, tune down to a protocol that ⁓ you know, traditional physicians think of if A, then B, right? There's just too many inputs, too many combinations, that the only way to really interpret this is to take this kind of a test and really follow the guidelines as computed and not as interpreted by a human. That brings me to the AI point that I was gonna make, which is that, you know, the number of data points we have here, it's it's in the tens of thousands. to say the least for the recommendations, the actual number of data points that we look for in the biome test is in the millions. And so we whittle that down to clusters of molecular functions that are relevant to biology, specific pathway biologies, and we bring it down to the point where it can be understood, interpreted, and then you can take an action on it. And that's why we have pathways in the order of, you know, more like a hundred. instead of just giving you the millions of data points just out of the out of the lab, right? So Vyomes AI, which we are showing here on the right hand side, takes the thousands and thousands of biological functions and maps it against the micronutrients and hundreds of different health conditions and comes up with a precise nutritional plan. So the way it does it, and you know we've talked about this in one of the ⁓ previous episodes, but just to recap, We have a food database already in bio right now. So we know the specific macro and micronutrients for each one of the foods in our food database. The macronutrients first goes through a glycemic response prediction step, which we also talked about in a previous episode. All the details behind it, the paper behind it, the science, the study, the population, all of those things are described in another episode. If you're interested in that, please listen to that episode. With an endocrinologist, Dr. Damon Tanton. That was the previous episode over there. And based on the glycemic response prediction, each food goes into either an enjoy bucket or a minimize bucket. And then, based on the micronutrients, we look at all of these pathways we were talking about earlier, whether it's a methane pathway, the butyrate pathway, the oxalate pathway, so on. And we then fine-tune the enjoy and minimize food. So we could potentially take an enjoy food and promote it, if it's gonna help your pathway, to a superfood, or we can demote it to an avoid food if it does not help your microphone. So in this case, I'm showing the example of someone whose spinach was in the enjoy food category after coming out of the glycemic response prediction. But if their oxalate elimination pathway is not very Good, meaning that's elimination is low, then that can drop down to an avoid food, like you see on the right hand side over here. And if it's good, meaning the elimination is high, it is in the superfood category. And the reason why oxalate is important, and we mentioned this in some other episodes, is that it can lead to kidney stones. So if you if you eat too much spinach when your oxalate is not being eliminated in your pathway. that could lead to kidney stores. That's the reason why this logic works this way. But every pathway has a similar logic for different micronutrients in the foods for the many foods that are in our database. And we go through that analysis one by one and we decide to put each food either in your superfoods, avoid ⁓ avoid foods, enjoy foods or minimize foods. That's what you see in the in the while map. And That's kind of the starting point. And you can also turn some of those into supplements, into probiotics, into prebiotics, and that can augment your basic food nutritional habits. Right? So that's how we end up with the food recommendations in the Biome app. And finally, you you may ask the question, okay, that's great that you're doing all that stuff. Does it really work? So we've done a bunch of randomized placebo-controlled trials. And Momo, you should probably explain each one of these things, please. Yeah, I can just highlight. These are all decentralized randomized placebo-controlled clinical trials run in the United States, mostly in adults. And ⁓ we have three boxes here for three separate trials. The one on the left, ⁓ we enrolled patients with IBS and ⁓ You can see here in the subgroup analysis of patients who had IBS constipation at baseline, 67% of them transitioned from constipation to healthy in three months with our personalized d nutrition. And only 9% transitioned from constipation to healthy in the placebo group. And that's very statistically and clinically significant. In the middle box, we're talking about reducing anxiety. So we were we were we ran a mental health trial in adults again, and we were able to transition. 50% of the people who had anxiety at the baseline back to healthy in three months versus 28% in the placebo group, and that's a statistically significant result. Last but not least, we were also able to reduce HBA1C, the major marker, biomarker of prediabetes and diabetes, in using our intervention. And this is obviously based on this glycemic model that Guru just described, where we were able to reduce HBA1C in a clinically meaningful ⁓ amount and statistically significantly in three months by point two eight percent in mostly pre diabetic people. So early sort of onset. And that's harder to do, right? Compared to, you know, diabetic people, right? Much harder, yeah. Yeah. Yeah, Momo, I mean that these numbers to me, ⁓ definitely with the IBS group, I mean it it's it it's shocking because, you know, I I I can tell you in in private practice, we do not make seventy percent of the people better with the things we do. So Yeah. Yeah, we are we are about to publish this paper, so it'll be really important to publish this and and share it with ⁓ the cl the the gastroenterology community. Yeah. Awesome. I have a question for Dr. Bass. Go for it. So given given what we just discussed, ⁓ and and speaking directly to another gastroentrologist, how would you recommend that gastroenterologist uses the GH Pro, the timing, the conditions? the intro you know, the the the the management of nutrition, follow-up, things like that. Can you paint sort of a realistic picture just yeah. Yeah. And and I think ⁓ so, you know, we so we, you know, have to kind of look at the use case, right? So if there's a patient that that's coming into a GI GI practice office, so that that patient isn't coming in here for prevention or or to to optimize health. They have a specific clinical question or a clinical issue that they want answered. Right. And so, you know, f first thing is to just just identify what is what is the actual clinical problem. Is it constipation? Is it bloating? Is it is it pain? Is it IBSD? Right. So that's so so so that's problem number one. But then two, you know, in in a standard GI practice, you know, we are we're seeing maybe fifteen, seventeen patients per day. So we we only have a limited, limited amount of time. And that's the one thing I actually love about Love About GH Pro because there's six things. It's lean and you know it it basically covers, you know, the vast the the the the vast majority of things we will see in a in a in a standard GI practice. So, you know, first step is is to just find what is that clinical problem that you're that you're trying to treat. Order the test. You'll get insights, you'll get you know, you'll find these these these these pathway breakdowns and you know based on those pathway breakdowns, you know, that's going to help guide guide treatment for you likely. Or, you know, it might move you into ordering further tests that would give you the the standard standard confirmation that that you know you know a patient has a a a certain issue or not. So ⁓ you know say say for ⁓ you know you know type two type two diabetes so if that DRS score is high you know, it's not that like a as the GI doctor, if we don't manage that then we would recommend following up with their with their primary care doctor, just getting a standard standard hemoglobin and A won't see. I mean we can we can even order that, but you know, it just helps triage patients into it into that right bucket. So you know, it's it's treatment management tailored to the actual right choice of of treatment as as opposed to this like trial and trial and error process where we just throw throw throw everything at the wall and and ⁓ And figure out which where do we triage the patient after that. Okay, but I'm also thinking, Dr. Bass, that there's an opportunity here because of a lot of people come for screening colonoscopies starting at the age of forty five, and they may not present with any symptoms, but I think it's an opportunity for them to do the gut test and see what they're at risk for, whether they have polyps or not. What do you think? No, I hundred percent agree with you. I mean ⁓ just just in in in in like a perfect world, I frankly I think Everybody be should everybody should be getting gut gut health pro or or even pH pro, right? I I think I think in a in a in a perfect world, ⁓ you know, it it's great to have a baseline. So, you know, we're s sourcing more and more data right now about how you know changes in the gut microbiome make an increase your risk of having polyps. Right. And and so ⁓ you know, I I would definitely if if if like that's possible, definitely, definitely recommend that just just as as as like a standard baseline. ⁓ I think. But it but if you look in the just typical, typical GI GI practice, ⁓ you know, again, volume of patients are extremely high, ⁓ time is time is limited, ⁓ you know, it it might not necessarily be the best setting to to get to practice test. ⁓ but but let's think about the the actual logistics. So let's say the through the process of a patient scheduling a screening colonoscopy ⁓ until they get the results, where would the ⁓ physician have the opportunity to encourage the patient to order the G H pro or to request it so that the physician can order it? Yeah, so well it depends. I mean so there's so i if it's just a standard standard screening colo, ⁓ a lot of the cases are are are actually booked straight to the surgical center. So so the doctor might not necessarily meet the patient un until the the the day of the actual test. So ⁓ you know, I mean I think th that I mean that that seems to be like a seems to be like a relatively easy, easy, easy problem to solve. Whereas that, you know, when when the patient's calling in just to make just to make a standard, standard screening colo, then they would just they would just automatically be be set up for a for a for a GH pro test. ⁓ you know, that that test would then just be mailed to them. They would give the sample at at home, but then they would mail it in. ⁓ you know, other option is is that if ⁓ the patient's seeing the doctor prior to that screen in colo, then then the doctor would just order that that G H pro at the time of that visit and then they would ⁓ you know, you know, do the test at at home and you know, and you know, frankly, I think I think in in in a screen in colo, there's plenty of plenty of opportunities to actually obtain stool samples. So, you know, it it's it's very, very rare that That when we're doing this ⁓ a screen of cold, there's no stool. So if if if the patient's sleeping and if there's stool there and if they can center that, I mean, is it is there like an opportunity to get stool at the No, unfortunately no, because the microbiome is going to be severely disturbed with the colon prep. ⁓ however, the good news is that what you described is everything prior to the colon prep, the patient can receive the kit and collect the sample or All they have to do is wait one week post colonoscopy. We just published one of the latest biome papers. We show that the microbiome completely restores after a week post colonoscopy. So the GH pro can be ordered actually while delivering the results of the colonoscopy, and then can be ordered and by the time the patient receives it, it's it's gonna be basically a week. Wow. That's great. Yeah. I know Yeah. That's awesome. Yeah, and and and you know, I I I wanna mention that we keep adding more and more disease screening capabilities into GH Pro over time as we collect more data, analyze more data, and we are able to get the right type of validation evidence for each disease area, we keep adding that. So like Momo mentioned, right, colon polyps would be an addition to GutHealth Pro in the in the near future. And ⁓ so you can get ⁓ an indication of you know whether you have colon polyps, what level it is, and so on and so forth. And over time I can see us getting into colon cancer, ⁓ early detection of colon cancer as well, which we know that the the signal already exists in this tool because we've done multiple internal studies in which we've already seen the signal. And there's also very significant evidence of. connection to all the systemic different processes in your body to the gut, right? So there's, you know, there's, you know, people talk about the gut brain axis, which means, you know, we already talked about depression and anxiety, but we could also go a step further. We could go into dementia. We can go into mild cognitive impairment. We can go into all of these other areas over time. We can also talk about the liver, gut-liver connection. We can talk about the gut heart connection, you know, so the the entire systemic health, call it the profile of an individual from the gut as the kind of the central body that ⁓ that kind of interacts with and and in many cases regulates the the ⁓ disease and the health processes can become part of the gut health protest. And that's one of the things that we are working towards in bio. We call it the multi disease early detection test. That's the kind of the concept for having a range of different diseases that we can detect through through a gut test. Yeah, that's a really ⁓ go ahead, Mike. Well so I I I I just wanted to double click on that on the entire colon polyp polyp aspect of it. So you know at at as as of now, so we prevent colon cancer by doing a scope and then removing that polyp. But what if we can shift it upstream and Yeah. where that polyp never forms in the first place. Right. So that's when I see the power of of, you know, eventually at some point, the, you know, power of of of of gut health pro. If we start, you know, seeing shifts in that in that microbiome that might indicate the patient's at risk for for hormone polyps, we can make make dietary dietary recommendations and we could possibly decrease that chance of them form polyps in the in the first place. So to me that that's incredibly incredibly exciting pathway for for for GI. Yeah, I want to say that ⁓ just want to highlight what summarize what Guru said is that ⁓ treat this test as a dynamic test. It's not like it's done and it will always be static like this like most other tests are. It's going to evolve as the science evolves and physicians can actually influence it what direction it's going to move into because if there's a physician that presents a very solid case as to why the condition they're interested in is important and and tied to the microbiome, we may study it and even physicians can work with us to actually create a study so that we can learn from it and then incorporate into the product. So this is really a platform. It's not really like a fixed test for like one marker and that's all you ever get. It's really a platform to serve the gastroenterology community for basically years and decades. So think of it that way. That's a great way to ⁓ end the episode, Momo. So, you know, it's a it's a kind of an invitation to work with us ⁓ both at the practice level day to day as well as at the research level strategically over time. So ⁓ thank you very much, ⁓ Mike, for joining us for this conversation. I'm sure we'll have you back here to talk about things that we're learning from the gut health pro ⁓ in the field in the future. But thank you so much for ⁓ joining us for the last hour. Thank you. Awesome. Thank you, Dr. Bass. Thank you, Mama. Yeah, that was great to have Mike on the discussion on the pod. ⁓ I think we learned a lot of things about how gastroenterologists behave. I think we hope to change the practice of gastroenterology by l looking at or for focusing more on the functional elements, not just on the structural elements like we've been talking about. And ⁓ of course, ⁓ in a few months we will get somebody from the gastroenterology community back on our show so we can talk about how things have changed in that community because we are going to be implementing the gut health protest in multiple gastroenterology practices. Yep. Amazing. Yeah. Love the episode. And ⁓ really the next the next sort of ⁓ Quantum leap in gastroenterology, enabling physicians to really look at the molecular under the hood and identify all the molecular reasons, and then, as we discussed, actually modulate the microbial functions and human physiology using micronutrients. I mean, that's really the holy grail is that you can ⁓ prescribe people diet and ⁓ and change their ⁓ physiology. Okay, so Guru, ⁓ the BioMonthly Challenge, let's remind the audience that. All they have to do is post questions on any one of our episodes. And we will consider those questions, answer them, of course, and we will consider them for our monthly challenge ⁓ for which the ⁓ reward is ⁓ the full body intelligence kit. So ⁓ what's in the next episodes, guru? Yeah, well, first of all, you know, ⁓ for our audience members, I want to say don't be shy. If you have a question in your head, just go ahead and post down below in the in the YouTube channel. And ⁓ we will definitely take a look. We will answer you perhaps on one of the next episodes. And if your answer your your question is really great and will help a lot of people, then you might end up getting a free full body intelligence, as Momo said. So looking ahead, ⁓ I mentioned last time that we have a number of really great leaders in the community joining us as guests. We had ⁓ an investment leader, Vinod Kosla. We ⁓ just had a gastroenterology leader. We're gonna continue to have biology leaders, scientific leaders, business leaders who are very much in the field of ⁓ longevity and ⁓ preventive medicine. And we are going to try and get interesting conversations going that will engage and educate everybody in this audience. So that's what is coming up in the summer. So excited. Alright, thank you guru so much. I am Momo, a biochemist. And I'm Guru, an AI scientist, and we're two PhDs on a park. Two PhDs on a pod is a Viome Health Science Podcast production. Written and hosted by Viome CTO Guru Banavar and Viome CSO Momo Vuyisic. Produced and edited by Lisa Shomo. Podcast Art by Kevin Wu. If you enjoyed today's episode, like and subscribe for new episodes every other week. We'll see you next time.